The main purpose of this legislation is to ensure that lung cancer biomarker testing is covered under the Medicare program. This testing is important for diagnosing and treating lung cancer more effectively by identifying specific biomarkers that can guide treatment decisions. Key provisions of the legislation include the requirement for Medicare to cover lung cancer biomarker testing starting January 1, 2027. The law defines lung cancer biomarker testing as tests that analyze a patient's tissue, blood, or bodily fluids to identify specific biomarkers related to lung cancer.